#CVCT is in da (ACC Heart) House ! Thank you American College of Cardiology & JACC Journals for your ongoing support and collaboration - and to Harlan Krumholz for such an inspiring speech ! Dr Roxana Mehran @JJheart_doc Faiez ZANNAD

In the med lit, statements like “to our knowledge [TOK], this is the FIRST...” often replace systematic searches. Among 4488 articles in 6 lead journals 2020-24, TOK prevalence = 21.7%, w PLOS Medicine highest (48.4%), NEJM lowest (1.3%) Nicola Di Girolamo Ugo Di Girolamo Cornell University College of Veterinary Medicine

How much do abstracts change between submission and publication through the #peerreview & #editorial process? We examined all #RCT abstracts submitted to NEJM in 2022➡️ 59% improved Presented at #PRC10 & published in Annals of Int Med bit.ly/42eVpjl Peer Review Congress #PRC10

Inspiring talk by NEJM AI EIC Isaac Kohane on the future of #peerreview and use of #AI for optimizing the #editorial process #PRC10 Peer Review Congress #PRC10 NEJM Evidence NEJM

Yesterday, Christos Kotanidis, MD, DPhil Chris Kotanidis presented "Revision of Research Abstracts Through the Editorial Process" at the 10th Annual International Peer Review Congress in Chicago. Read the study in Annals here: bit.ly/41ADLGJ Peer Review Congress #PRC10 #peerreview

Exciting times! 33yrs after #SOLVDPrevention, 2 #CVprev RCTs have just been launched specifically designed to *prevent* HF in T2D+HTN+ASCVD #PREVENTHF (n=11,300) combo #ASi baxdrostat + #SGLT2i dapagliflozin #EASiPROTKT (n=11,800) combo #ASi vicadrostat + #SGLT2i empagliflozin

BETAMI–DANBLOCK trial: Beta-blockers are recommended for myocardial infarction and reduced left ventricular ejection fraction, but potential benefits for preserved or mildly reduced ejection fraction are unclear. Research findings are summarized in a new Quick Take video.

One of the rare moments we as a medical community are recognized in the public eye. Thank you to Noah Wyle for dedicating his #Emmys win to healthcare workers. 👏 #HealthcareHeroes #MedTwitter #Emmys2025 #ThankYou #FrontlineHeroes #Doctors #nurses

A great cover letter can make or break your manuscript submission. As an editor and author, I've seen how a strong cover letter helps editors grasp your paper’s significance. 🧵 [1/9]

Presented at #ESMO25: Among participants with advanced pheochromocytoma or paraganglioma, belzutifan showed durable antitumor activity and a reduced need for antihypertensives, although most participants had treatment-related adverse events. Full LITESPARK-015 phase 2 trial

Presented at #AHA25: In patients with atrial fibrillation after successful ablation, rivaroxaban therapy did not lead to a significantly lower incidence of a composite of stroke, systemic embolism, or new covert embolic stroke than aspirin therapy. Full OCEAN trial results:

Original Article: Evolocumab in Patients without Previous Myocardial Infarction or Stroke (VESALIUS-CV trial) nej.md/4oWrIN6 Editorial: VESALIUS and the Anatomy of High-Risk Prevention nej.md/4onnePw AHA Science | #AHA25

Presented at #AHA25: In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: nej.md/43U5Ppo AHA Science

In patients with cardiovascular disease and an implantable cardioverter–defibrillator, increasing potassium levels to the high-normal range reduced the risk of arrhythmia events, hospitalizations, and death. Full POTCAST trial results and Research Summary: nej.md/4oQtHTN

The clinical importance of the timely diagnosis of long QT syndrome stems from the fact that sudden cardiac death is often the first symptom, which makes remedying diagnostic or therapeutic errors impossible. Learn more about long QT syndrome in a new review:

This Saturday we were so happy to see Chris Kotanidis coming directly from Oxford 🇬🇧 what a wonderful young clinician & researcher - future star in our field 🌟🌟

#MedStats masterclass at #CVCT2025 with lots of engaging conversations around #RCT design, analysis and the win ratio in particular. If you’re wondering how Win Ratios work, this NEJM Evidence Stats STAT! may help. evidence.nejm.org/doi/full/10.10… CVCT - CardioVascular Clinical Trialists Faiez ZANNAD

HTD1801, an oral anti-inflammatory metabolic modulator, shown to improve #eGFR in patients with #T2DM & #CKM. #LBCT #CVCT2025 CVCT - CardioVascular Clinical Trialists

Editorial by Raja-Elie E. Abdulnour, MD (Raja-Elie Abdulnour), and Eric J. Rubin, MD, PhD: NEJM Clinician — Finding the Medicine That Matters in an Age of Infinite Evidence nej.md/4roG5vK #MedTwitter

Can #AI help with events adjudication in #RCTs? Important insights by Jonathan Cunningham from Brigham and Women's Hospital & Kieran Docherty from University of Glasgow #LBCT #CVCT2025